Scarica l'app Stockscreener
108.62
1.06%
1.14
Dopo l'orario di chiusura:
104.04
-4.58
-4.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
Mirum Pharmaceuticals Reports Strong Q4 2025 Earnings and 2026 Guidance - Intellectia AI
Mirum Pharmaceuticals (MIRM) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Mirum Pharmaceuticals Files For Offering Of Up To 8.96 Million Shares Of Common Stock By The Selling Stockholders - TradingView
Mirum (MIRM) Q4 2025 Earnings Call Transcript - AOL.com
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), Mirum Pharmaceuticals, Inc. has officially registered a public offering plan of common stock initiated by selling shareholders. - Bitget
Earnings call transcript: Mirum Pharmaceuticals’ Q4 2025 revenue exceeds expectations - Investing.com
Mirum Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update - Business Wire
Mirum Pharmaceuticals earnings up next as pipeline readouts loom - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A Biotech Powerhouse with 9.63% Potential Upside - DirectorsTalk Interviews
Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After Its 115% One-Year Surge? - Yahoo Finance
Insights Ahead: Mirum Pharmaceuticals's Quarterly Earnings - Benzinga
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - bdtonline.com
Will Mirum Pharmaceuticals Inc. stock hit new highs in YEARJuly 2025 Snapshot & Weekly High Return Stock Forecasts - mfd.ru
Mirum Pharmaceuticals (NASDAQ:MIRM) Research Coverage Started at Royal Bank Of Canada - Defense World
Portfolio Recap: Will Mirum Pharmaceuticals Inc stock hit new highs in YEARJuly 2025 Review & Risk Controlled Daily Plans - baoquankhu1.vn
Mirum Pharmaceuticals (NASDAQ:MIRM) Raised to "Moderate Buy" at Royal Bank Of Canada - MarketBeat
Mirum Pharmaceuticals stock reaches all-time high at 106.27 USD By Investing.com - Investing.com Canada
Earnings Recap: Can Mirum Pharmaceuticals Inc benefit from deglobalizationJuly 2025 Trends & Free Community Consensus Stock Picks - baoquankhu1.vn
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 - Bluefield Daily Telegraph
Drugmaker Mirum sets Feb. 25 call on 2025 results - Stock Titan
User - The Chronicle-Journal
RBC Capital Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Outperform Recommendation - Nasdaq
Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week HighTime to Buy? - MarketBeat
Mirum Can Sustain Revenue Growth with Multiple Catalysts, RBC Says - marketscreener.com
Mirum Pharmaceuticals stock reaches all-time high at 106.27 USD - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release - Yahoo Finance
Mirum Pharmaceuticals (MIRM) Expected to Announce Earnings on Wednesday - MarketBeat
Saira Ramasastry, Mirum director, sells $204k in shares By Investing.com - Investing.com Canada
Saira Ramasastry, Mirum director, sells $204k in shares - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A Biotech Gem with 11.25% Upside Potential - DirectorsTalk Interviews
TimesSquare Capital Management LLC Makes New $22.04 Million Investment in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Is Mirum Pharmaceuticals Inc. a turnaround storyDollar Strength & Real-Time Stock Price Movement Reports - mfd.ru
Why Mirum Pharmaceuticals Inc. stock is trending among retail traders - mfd.ru
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Embodies the Minervini Growth Momentum Strategy - ChartMill
What are analysts’ price targets for Mirum Pharmaceuticals Inc.Earnings Summary Report & Weekly Sector Rotation Insights - mfd.ru
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Will Mirum Pharmaceuticals Inc. benefit from AI trendsShare Buyback & Expert Verified Stock Movement Alerts - mfd.ru
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MEXC
Mirum Pharmaceuticals Grants Stock Awards to New Employees - Intellectia AI
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Offers a High-Growth Momentum and Technical Breakout Setup - ChartMill
Candriam S.C.A. Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals expands portfolio in rare disease drug focus - Traders Union
Gap Down: Can Mirum Pharmaceuticals Inc benefit from deglobalizationJuly 2025 PreEarnings & Fast Entry Momentum Alerts - baoquankhu1.vn
Health Canada approves Livmarli for PFIC and ALGS - The Pharma Letter
Mirum Pharmaceuticals, Inc. $MIRM Shares Purchased by Penserra Capital Management LLC - MarketBeat
Sentiment Review: Is Mirum Pharmaceuticals Inc a turnaround storyFed Meeting & Safe Entry Trade Signal Reports - baoquankhu1.vn
Health Canada LIVMARLI Decision And Bluejay Deal Shape Mirum Outlook - Yahoo Finance
Mirum Pharmaceuticals says Health Canada authorizes Livmarli for cholestatic pruritus in progressive familial intrahepatic cholestasis (PFIC) patients - marketscreener.com
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome - BioSpace
Mirum Pharmaceuticals Stumbles on Health Canada Approval - Baystreet.ca
Mirum Pharmaceuticals' Tablet Formulation of its Cholestasic Pruritus Treatment Livmarli Approved in Canada - marketscreener.com
for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) - Business Wire
Is Mirum Pharmaceuticals on a Strong Path to Profitability? - AOL.com
Hot Picks: Small-cap pharma stocks in focus as key drug approvals near - BNN Bloomberg
Mirum Pharmaceuticals (MIRM) Price Target Increased by 10.50% to 116.99 - Nasdaq
1.52%
1.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):